Clinical Research · asia
Ivonescimab Plus Chemotherapy: Seven in Ten Surgical Patients Achieve Major Pathological Response in Phase 2 Lung Cancer Trial
A dual-targeting antibody used before and after lung cancer surgery has shown early evidence of substantial tumor regression. But the results come from patients who completed surgery, and randomized trials are needed to determine whether it reduces recurrence more effectively than current treatments.
Surgical removal of lung cancer does not mean the risk of recurrence disappears. Eliminating more cancer cells before and after surgery remains an ongoing goal of treatment development. A phase 2 study published in *Nature Medicine* on November 4 showed that, after ivonescimab plus chemotherapy, 47 of the 67 patients who completed surgery achieved a major pathological response, a rate of 70.1%, exceeding the study’s prespecified historical control threshold.
Ivonescimab targets both the immune checkpoint PD-1 and vascular endothelial growth factor, VEGF, seeking to combine relief of immune suppression with inhibition of tumor blood vessel formation. This nonrandomized trial enrolled 90 patients with resectable stage II–IIIB non-small cell lung cancer, excluding those with sensitizing EGFR mutations or ALK rearrangements; 79 received the drug plus chemotherapy, and 11 received monotherapy, followed by ivonescimab after surgery.
Major pathological response reflects the extent of tumor regression in tissue removed after treatment. The lower bound of the two-sided 80% confidence interval for the combination group’s 70.1% response rate exceeded the prespecified historical control value of 41%, meeting the primary endpoint. However, this was a comparison with historical data, without a concurrent randomized control group, so it cannot yet support a claim of superiority over current immunotherapy plus chemotherapy.
Bioon’s summary of the same study also noted that 50.7% of patients who completed surgery in the combination group achieved a pathological complete response, meaning no residual viable cancer cells were found in the specimens; all patients who underwent surgery in both groups achieved R0 resection, with no cancer cells found at the surgical margins. The denominators for these results require careful attention: the combination group initially included 79 patients, of whom 67 actually underwent surgery. Response rates among surgical patients cannot be directly applied to all enrolled patients, nor do they mean that patients have been cured.
Safety was assessed in the treated population: 24 of the 79 patients in the combination group experienced grade 3 or higher treatment-related adverse events, accounting for 30.4%. The study recorded no grade 3 or higher bleeding or treatment-related deaths, and one patient had surgery delayed for treatment-related reasons. These observations provide indications of the regimen’s safety before surgery, but a small study still has limited ability to fully characterize rare risks.
The combination group’s 12-month event-free survival rate was 83.3%, while data on median event-free survival remained immature. Pathological response can provide an earlier indication of drug activity, but recurrence and survival—the outcomes patients truly care about—require longer follow-up. The small sample, lack of a randomized control group, and limited long-term efficacy data make the current results more suitable as a basis for larger confirmatory studies.
Background Context
Evidence in lung cancer treatment must be understood in the context of disease stage and molecular characteristics. Comparative findings for targeted drugs in advanced lung cancer cannot be directly applied to patients with resectable disease; this study asks whether a dual-targeting antibody can improve treatment before and after surgery. The key next step is to use larger randomized trials to determine whether pathological regression translates into fewer recurrences and longer survival, while assessing the associated treatment burden.